Projects per year
Personal profile
Education
- 1983 MD, College of Medicine, National Taiwan University
Research Interests
- Cell Signaling Transduction
- Nanomedicine
- Oncology
- Clinical Trial
Experience
- 2004/08~now Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University
- 2017/08~now Director, Department of Internal Medicine, National Cheng Kung University Hospital
- 2004/07~now Chief, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
- 1990/08~now Attending Physician, National Cheng Kung University Hospital
- 2011/10~2017/07 Director, Cancer Center, National Cheng Kung University Hospital
- 2006/01~2011/09 Director, Clinical Trial Center, National Cheng Kung University Hospital
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Wu-Chou Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 26 Finished
-
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Sands, J., Ahn, M. J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Tostivint, E. P., Goto, Y., Yoh, K., Heist, R., Shimizu, J., Lee, J. S., Baas, P., Planchard, D., Pérol, M., Felip, E., Su, W. C., Zebger-Gong, H., Lan, L. & Liu, C. & 3 others, , 2025 Apr, In: Journal of Clinical Oncology. 43, 10, p. 1254-1265 12 p.Research output: Contribution to journal › Article › peer-review
Open Access40 Citations (Scopus) -
Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response
Hsieh, H. C., Young, M. J., Chen, K. Y., Su, W. C., Lin, C. C., Yen, Y. T., Hung, J. J. & Wang, Y. C., 2025 Apr 18, In: Science Advances. 11, 16, eadt4258.Research output: Contribution to journal › Article › peer-review
Open Access5 Citations (Scopus) -
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Lee, C. K., Liao, B. C., Subramaniam, S., Chiu, C. H., Mersiades, A. J., Ho, C. C., Brown, C., Lai, C. L., Hughes, B. G. M., Yang, T. Y., O'Byrne, K., Luo, Y. H., Yip, S., Ho, C. L., Bray, V., Su, W. C., Moore, M., Feng, W. L., Bai, Y. Y. & Ford, K. & 5 others, , 2025 Feb, In: JTO Clinical and Research Reports. 6, 2, 100771.Research output: Contribution to journal › Article › peer-review
Open Access -
Frailty and Intrinsic Capacity as Predictors of Recovery in Older Patients Surgically Treated for Cancer: A Longitudinal Study
Hu, F. W., Sun, C. Y., Su, W. C. & Chang, C. M., 2025, (Accepted/In press) In: Cancer Nursing. 10.1097/NCC.0000000000001497.Research output: Contribution to journal › Article › peer-review
-
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
Chiang, N. J., Lee, J. H., Chen, M. H., Chao, Y., Su, W. C., Bai, L. Y., Wu, S. Y., Hsu, C. H., Shan, Y. S., Li, C. P., Chen, S. H., Chung, W. P., Hao, W. H., Chen, L. T. & Lin, C. C., 2025 Apr 1, In: Oncologist. 30, 4, oyaf051.Research output: Contribution to journal › Article › peer-review
Open Access